Covid 19 Research using Clinical Trials (Home Page)
Report for D015231: Sexually Transmitted Diseases, Bacterial NIH
(Synonyms: Sexually Transmitted Diseases, Bacterial)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3030 | Usual Care plus Customized Referrals Wiki | 1.00 |
| drug1769 | Mobile Enhanced Prevention Support Wiki | 1.00 |
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012749 | Sexually Transmitted Diseases NIH | 1.00 |
| D006526 | Hepatitis C NIH | 1.00 |
| D019966 | Substance-Related Disorders NIH | 0.33 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Prevention Support for People Leaving Jail Study
This study will provide HIV prevention and related support services to men who have sex with men and transgender women who have substance use disorders and are either leaving jail or recently released from jail, living in a residential facility providing substance use services or supportive housing . The researchers will compare the utilization of HIV prevention and other support services between individuals who receive routine case management provided following enrollment to those who have access to GeoPassport, a global position service (GPS)-based mobile app, incentives, and peer mentor support.
NCT04036396 HIV Infections Sexually Transmitted Diseases, Bacterial Hepatitis C Substance Use Disorders Behavioral: Mobile Enhanced Prevention Support Behavioral: Usual Care plus Customized Referrals MeSH:Sexually Transmitted Diseases Sexually Transmitted Diseases, Bacterial Hepatitis C Substance-Related Disorders
Primary Outcomes
Description: Defined as the participant identifying and completing an appointment with a primary care provider who is willing and able to prescribe HIV pre-exposure prophylaxis. Provide documentation of the appointment.
Measure: Number of participants establishing a primary care provider who can prescribe PrEP (pre-exposure prophylaxis) Time: 9 monthsDescription: Defined as the participant completing the screening process for PrEP with an eligible provider or PrEP navigator. Provide documentation of the appointment.
Measure: Number of participants obtaining screening for PrEP Time: 9 monthsDescription: Defined as the participant obtaining a prescription for PrEP, providing documentation, reporting taking the medication
Measure: Number of participants who initiate PrEP regimen Time: 9 monthsDescription: Defined as the participant self-reporting taking prescribed PrEP at least 4 days per week over the prior 30 days
Measure: Number of participants who demonstrate minimal adherence to PrEP Time: 30 daysDescription: The participant will provide documentation of filled PrEP prescriptions for 3 or more months
Measure: Number of participants who remain on PrEP for at least 3 months. Time: 3 monthsDescription: Defined as the participant self-reporting having obtained HIV testing every 3 months over the 12 month follow-up period
Measure: Number of participants who undergo a HIV test every 3 months Time: 9 monthsDescription: Defined by the participant self-reporting having obtained testing for these 3 bacterial sexually transmitted diseases (STDs) every 6 months over the 12 month follow-up period
Measure: Number of participants who undergo a test for gonorrhea, syphilis, and chlamydia every 6 months Time: 9 monthsDescription: Defined by the participant self-reporting having obtained at least one test for Hepatitis C
Measure: Number of participants who undergo a test for hepatitis C Time: 9 monthsDescription: Defined by the participant self-report of completing initial recommended SUD appointments within 3 months of jail release, consistent with each participant's recommended American Society of Addiction Medicine (ASAM) level of care
Measure: Number of participants obtaining treatment for substance use disorders (SUDs) in the community Time: 3 monthsDescription: Defined by the participant self-reporting remaining engaged in treatment (i.e., continuing to attend meetings, counseling or other treatment activities) as defined by the recommended ASAM level of care in the 3 months prior to each follow-up interview.
Measure: Number of participants who remain engaged in treatment for substance use disorders (SUDs) in the community, Time: 3 monthsSecondary Outcomes
Description: Self-report of whether or not participants received follow-up care and treatment for HIV, STD, and hepatitis C infections diagnosed during study follow-up (n=300)
Measure: Number of participants in each arm receiving care and treatment for newly diagnosed HIV or STD infections. Time: 9 monthsDescription: Measure the comparative effectiveness of each intervention arm on reducing recidivism (n=300), quantified as the number of respondents who are reincarcerated and the total number of reincarcerations per arm over the study period.
Measure: Number of participants in each arm experiencing recidivism Time: 9 monthsDescription: Describe the temporal distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=150).
Measure: Temporal service utilization patterns of intervention arm participants Time: 9 monthsDescription: Report the geographic distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=150).
Measure: Geographic service utilization patterns of intervention arm participants Time: 9 months